What happens when patients stop anti-CGRP monoclonal antibody treatment? A recent study using the CGRP (human) ELISA kit (#A05481) revealed an unexpected finding: migraine frequency increased significantly after eight months of therapy discontinuation, even though plasma-free CGRP levels remained unchanged.
This means that the worsening of migraine symptoms cannot be explained by free CGRP levels alone. Therefore, monitoring both Free CGRP and Total CGRP levels is essential when studying CGRP physiology during or after CGRP-targeted treatment.
Understanding these dynamics is crucial, and selecting the right tools for biomarker interpretation can make a real difference — as demonstrated by the use of Bertin Bioreagent products in this case.
